Pfizer (NYSE:PFE) Stock Acquired Rep. Bruce Westerman

Posted by Lindsey Winhoffer on Apr 18th, 2025

Representative Bruce Westerman (R-Arkansas) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on March 3rd. The trade occurred in the Representative’s “FISHER IRA” account.

Representative Bruce Westerman also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of LVMH Moët Hennessy – Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 4/2/2025.
Purchased $1,001 – $15,000 in shares of Sony Group (NYSE:SONY) on 3/24/2025.
Purchased $1,001 – $15,000 in shares of Mitsubishi UFJ Financial Group (NYSE:MUFG) on 3/21/2025.
Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 3/21/2025.
Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 3/20/2025.
Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 3/20/2025.
Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 3/20/2025.
Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/20/2025.
Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/20/2025.
Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/20/2025.

Pfizer Stock Performance

PFE opened at $22.13 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $24.95 and its 200-day moving average is $26.23. The stock has a market cap of $125.50 billion, a PE ratio of 15.69, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the business earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Institutional Trading of Pfizer

Several large investors have recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $27,000. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group decreased their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research note on Tuesday, April 8th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.07.

Read Our Latest Analysis on Pfizer

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas’ 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 4th Congressional District. He declared candidacy for the 2026 election.

Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About Pfizer

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.